Ruben G. Zamorano
University of Texas at San Antonio
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ruben G. Zamorano.
Diabetes Care | 2007
Lawrence A. Lavery; Kevin R. Higgins; Dan R. Lanctot; George Constantinides; Ruben G. Zamorano; Kyriacos A. Athanasiou; David Armstrong; C. Mauli Agrawal
OBJECTIVE—The purpose of this study was to evaluate the effectiveness of a temperature monitoring instrument to reduce the incidence of foot ulcers in individuals with diabetes who have a high risk for lower extremity complications. RESEARCH DESIGN AND METHODS—In this physician-blinded, randomized, 15-month, multicenter trial, 173 subjects with a previous history of diabetic foot ulceration were assigned to standard therapy, structured foot examination, or enhanced therapy groups. Each group received therapeutic footwear, diabetic foot education, and regular foot care. Subjects in the structured foot examination group performed a structured foot inspection daily and recorded their findings in a logbook. If standard therapy or structured foot examinations identified any foot abnormalities, subjects were instructed to contact the study nurse immediately. Subjects in the enhanced therapy group used an infrared skin thermometer to measure temperatures on six foot sites each day. Temperature differences >4°F (>2.2°C) between left and right corresponding sites triggered patients to contact the study nurse and reduce activity until temperatures normalized. RESULTS—The enhanced therapy group had fewer foot ulcers than the standard therapy and structured foot examination groups (enhanced therapy 8.5 vs. standard therapy 29.3%, P = 0.0046 and enhanced therapy vs. structured foot examination 30.4%, P = 0.0029). Patients in the standard therapy and structured foot examination groups were 4.37 and 4.71 times more likely to develop ulcers than patients in the enhanced therapy group. CONCLUSIONS—Infrared temperature home monitoring, in serving as an “early warning sign,” appears to be a simple and useful adjunct in the prevention of diabetic foot ulcerations.
International Wound Journal | 2015
Lawrence A. Lavery; Kevin R. Higgins; Javier La Fontaine; Ruben G. Zamorano; George Constantinides; Paul J. Kim
The objective of this study was to evaluate the efficacy of three off‐loading techniques to heal diabetic foot wounds: total contact casts (TCCs), healing sandals (HSs) and a removable boot with a shear‐reducing foot bed (SRB). This was a 12‐week, single‐blinded randomised clinical trial with three parallel treatment groups of adults with diabetes and a foot ulcer (n = 73). Ulcer healing was defined as full reepithelialisation with no drainage. Diabetic patients with grade UT1A or UT2A forefoot ulcers on the sole of the foot were enrolled. Patients with malignancy, immune‐compromising diseases, severe peripheral vascular disease (ankle‐brachial index < 0·60 or transcutaneous oxygen < 25 mm/Hg), alcohol or substance abuse within 6 months, untreated osteomyelitis or Charcot arthropathy with residual deformity that would not fit the HS or boot were excluded. In the intent‐to‐treat analysis, significantly higher proportion of patients were healed in the TCC group (69·6%) compared to those treated with the SRB (22·2%, P < 0·05). There was no difference in the rate of healed ulcers in the HS (44·5%) and TCC groups. Ulcers in the TCC group healed faster than those in the HS group (5·4 ± 2·9 versus 8·9 ± 3·5 weeks, P < 0·02). However, there was no difference in the time to healing in the TCC and SRB groups (6·7 ± 4·3 weeks, P = 0·28). Patients who used HS were significantly more active (4022 ± 4652 steps per day, P < 0·05) than those treated with TCCs (1447 ± 1310) or SRB (1404 ± 1234). It is concluded that patients treated with TCCs had the highest proportion of healed wounds and fastest healing time. The novel shear‐reducing walker had the lowest healing and highest rate of attrition during the study.
Diabetes Care | 2004
Lawrence A. Lavery; Kevin R. Higgins; Dan R. Lanctot; George Constantinides; Ruben G. Zamorano; David Armstrong; Kyriacos A. Athanasiou; C. Mauli Agrawal
Archive | 2001
Lawrence A. Lavery; C. Mauli Agrawal; Kyriacos A. Athanasiou; George Constantinides; Dan R. Lanctot; Ruben G. Zamorano
Archive | 2000
Lawrence A. Lavery; Mauli Agrawal; Kyriacos A. Athanasiou; George Constantinides; Dan R. Lanctot; Ruben G. Zamorano
Diabetes Technology & Therapeutics | 2005
Lawrence A. Lavery; Dan R. Lanctot; George Constantinides; Ruben G. Zamorano; Kyriacos A. Athanasiou; C. Mauli Agrawal
Archive | 2000
Lawrence A. Lavery; Dan R. Lanctot; Ruben G. Zamorano
Archive | 2001
Lawrence A. Lavery; Mauli Agrawal; Kyriacos A. Athanasiou; George Constantinides; Dan R. Lanctot; Ruben G. Zamorano
Archive | 2002
Lawrence A. Lavery; C. Mauli Agrawal; Kyriacos A. Athanasiou; George Constantinides; Dan R. Lanctot; Ruben G. Zamorano
Archive | 2001
Lawrence A. Lavery; Dan R. Lanctot; Ruben G. Zamorano
Collaboration
Dive into the Ruben G. Zamorano's collaboration.
University of Texas Health Science Center at San Antonio
View shared research outputsUniversity of Texas Health Science Center at San Antonio
View shared research outputsUniversity of Texas Health Science Center at San Antonio
View shared research outputs